ATE269712T1 - Stabilisierte herpesvirusformulierung - Google Patents

Stabilisierte herpesvirusformulierung

Info

Publication number
ATE269712T1
ATE269712T1 AT99919380T AT99919380T ATE269712T1 AT E269712 T1 ATE269712 T1 AT E269712T1 AT 99919380 T AT99919380 T AT 99919380T AT 99919380 T AT99919380 T AT 99919380T AT E269712 T1 ATE269712 T1 AT E269712T1
Authority
AT
Austria
Prior art keywords
stabilized
herpes virus
virus
virus formulation
aminoacids
Prior art date
Application number
AT99919380T
Other languages
English (en)
Inventor
Claire Alison Varley
Peter Thomas Loudon
Original Assignee
Cantab Pharmaceuticals Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Pharmaceuticals Res Ltd filed Critical Cantab Pharmaceuticals Res Ltd
Application granted granted Critical
Publication of ATE269712T1 publication Critical patent/ATE269712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99919380T 1998-04-24 1999-04-26 Stabilisierte herpesvirusformulierung ATE269712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9808922A GB9808922D0 (en) 1998-04-24 1998-04-24 Virus preparations
PCT/GB1999/001295 WO1999055348A2 (en) 1998-04-24 1999-04-26 Stabilised virus preparation

Publications (1)

Publication Number Publication Date
ATE269712T1 true ATE269712T1 (de) 2004-07-15

Family

ID=10831020

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99919380T ATE269712T1 (de) 1998-04-24 1999-04-26 Stabilisierte herpesvirusformulierung

Country Status (12)

Country Link
US (1) US6258362B1 (de)
EP (1) EP1071438B1 (de)
JP (1) JP2002512970A (de)
AT (1) ATE269712T1 (de)
AU (1) AU3718299A (de)
CA (1) CA2329000C (de)
DE (1) DE69918283T2 (de)
DK (1) DK1071438T3 (de)
ES (1) ES2224646T3 (de)
GB (1) GB9808922D0 (de)
PT (1) PT1071438E (de)
WO (1) WO1999055348A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
CA2417274A1 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Respiratory syncytial virus vaccines
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
AU2008201215B2 (en) * 2001-12-10 2010-11-18 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
HUP0402179A3 (en) * 2001-12-10 2012-09-28 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
WO2004073736A1 (es) * 2003-02-20 2004-09-02 Centro Nacional De Investigaciones Cientificas (Cnic) Cepas atenuadas de vibrio cholerae y vacunas liofilizadas que las contienen
US7435422B2 (en) 2004-01-15 2008-10-14 Intervet International B.V. Non-animal origin stabilizers and processes for producing the same
US8916175B2 (en) * 2004-06-29 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection
AU2005304866B2 (en) 2004-11-05 2010-04-01 Wellstat Biologics Corporation Stable and filterable enveloped virus formulations
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
BRPI0614601A2 (pt) * 2005-08-04 2012-01-31 Wyeth Corp formulação de vacina animal; componente estabilizador; vacina animal; processo de preparação de uma formulação de vacina animal; estabilizador de vacina; e componente estabilizador de vacina
US8097245B2 (en) 2005-12-28 2012-01-17 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2008079539A2 (en) 2006-11-09 2008-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant herpesvirus with diminished latency and methods of using same
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
WO2010044365A1 (ja) * 2008-10-17 2010-04-22 国立大学法人東京海洋大学 鮮度測定用試薬キット
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
PL2435554T3 (pl) * 2009-05-26 2018-01-31 Advanced Bionutrition Corp Stabilna kompozycja suchego proszku zawierająca biologicznie aktywne mikroorganizmy i/lub materiały bioaktywne i sposoby jej wykonania
AR080073A1 (es) 2010-01-28 2012-03-14 Advanced Bionutrition Corp Composicion vitrea seca que comprende un material bioactivo
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
BR112013003244B1 (pt) 2010-08-13 2018-07-17 Advanced Bionutrition Corp composição seca estabilizante para material biológico, seu método de preparação, e formulação de carreamento oral
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
CN103347535B (zh) 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 液体病毒制剂
EP2802649B1 (de) 2012-01-09 2017-08-09 Sanofi Pasteur Biologics, LLC Aufreinigung von herpesvirus
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
FR3024780B1 (fr) * 2014-08-07 2018-11-30 Bertin Pharma Reactif pret a l'emploi
JP6889699B2 (ja) 2015-07-29 2021-06-18 アドバンスド バイオニュートリション コープ． 特定栄養用途のための安定乾燥プロバイオティクス組成物
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
WO2020113197A1 (en) * 2018-11-30 2020-06-04 Vaccine Stabilization Institute Viral formulations containing amino acids

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209738C (de)
GB960850A (en) * 1961-09-08 1964-06-17 Wellcome Found Measles virus vaccine
JPS4848621A (de) * 1971-10-20 1973-07-10
JPS4868730A (de) * 1971-12-21 1973-09-19
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5648488B2 (de) * 1973-06-06 1981-11-16
JPS5341202B2 (de) * 1974-03-12 1978-11-01
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
AU532186B2 (en) * 1978-07-21 1983-09-22 Merck & Co., Inc. Herpes virus vaccine
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0048194A3 (de) * 1980-08-28 1982-09-01 Merck & Co. Inc. Verfahren zur Lyophilisierung
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
HU183765B (en) * 1981-12-23 1984-05-28 Phylaxia Oltoanyagtermeloe Process for producing lyophilized vaccine against duck hepatitis
DK331087A (da) 1986-06-30 1987-12-31 Smith Kline Rit Stabilisator for levende vaccine
JPS63230851A (ja) * 1987-03-20 1988-09-27 Sumitomo Metal Ind Ltd 耐食性に優れた油井管用低合金鋼
IE61575B1 (en) 1987-05-04 1994-11-16 Merck & Co Inc A stable lyophilized live herpes virus vaccine
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
FR2633518B1 (fr) 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
JP3895366B2 (ja) 1990-09-25 2007-03-22 キャンタブ ファーマシューティカルズ リサーチ リミティド ウィルス ワクチン
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
PT713397E (pt) 1992-03-24 2003-04-30 United Cancer Res Inst Vacina que contem virus vivos
JPH06234659A (ja) 1992-05-05 1994-08-23 Handai Biseibutsubiyou Kenkyukai 安定化生ワクチン
CZ289574B6 (cs) 1992-06-04 2002-02-13 Merck And Co., Inc. Způsob výroby ľivé, atenuované vakcíny viru varicella zoster
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
CA2158935A1 (en) 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
EP0872249A4 (de) 1995-03-17 2001-10-24 Hisamitsu Pharmaceutical Co Gentransferpräparation
JP2000507963A (ja) 1996-12-20 2000-06-27 メルク エンド カンパニー インコーポレーテッド 凍結乾燥ワクチン用安定剤

Also Published As

Publication number Publication date
ES2224646T3 (es) 2005-03-01
EP1071438B1 (de) 2004-06-23
PT1071438E (pt) 2004-11-30
EP1071438A2 (de) 2001-01-31
JP2002512970A (ja) 2002-05-08
GB9808922D0 (en) 1998-06-24
DK1071438T3 (da) 2004-10-25
WO1999055348A2 (en) 1999-11-04
CA2329000A1 (en) 1999-11-04
AU3718299A (en) 1999-11-16
CA2329000C (en) 2010-03-23
DE69918283D1 (de) 2004-07-29
US6258362B1 (en) 2001-07-10
WO1999055348A3 (en) 1999-12-16
DE69918283T2 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
ATE269712T1 (de) Stabilisierte herpesvirusformulierung
IL124941A0 (en) Formulations of nerve growth factor suitable for lyophilization
NZ337885A (en) vaccine formulation of an antigen, a TH-1 inducing adjuvant and a sparingly water soluble amino acid
MX9604907A (es) Vacuna de combinacion de virus para la enfermedad de newcastle.
TR200002930T2 (tr) Kolaylaştırıcı kompozisyonlar
BRPI0107737B1 (pt) vírus do herpes simplex 1 (hsv1), uso do hsv1, e, composição farmacêutica
AU1198697A (en) Stabilizers for live vaccines
AU1271799A (en) Methods for preventing and treating bacterial infections using cellulose ace tatephthalate or hydroxypropyl methylcellulose phthalate excipients
AU2497292A (en) Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
NO985094D0 (no) Polymerpulver som er redispergerbart i vandige l°sninger
AU4622693A (en) Potentiation of immunogenic response
GR3030834T3 (en) Herpes simplex virus vp16 vaccines
US20080241187A1 (en) Stabilization of viral compositions
ES2056042T1 (es) Copolimeros solubles en agua de acetato de vinilo y acido maleamico. uso como fluidizadores o reductores de agua de alto alcance para suspensiones acuosas.
AR026637A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para uso en vacas gestantes
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
EP0692974A4 (de) Multikomponentenimpfstoff aus clostridien, der saponin als adjuvans benutzt
HUP0001991A2 (hu) Varicella Zoster vírus 63-as géntermékkel szembeni vakcinák
EP1144009A3 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
CA2116355A1 (en) Infectious bovine rhinotracheitis virus mutants and vaccines
BR0012985A (pt) Vacina, bactéria, uso da mesma, e composição farmacêutica e métodos de tratamento ou prevenção de doença mediada por hsv em um hospedeiro humano ou animal e de uma infecção viral da mucosa de um hospedeiro humano ou animal
AR009866A1 (es) Formulacion inmunopotenciadora para uso vacunal
PT100460A (pt) Partiiculas derivadas de virus de herpes e vacinas que as contem
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
林建安 et al. Composition of HT-7 LHCD and its Protection Systems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071438

Country of ref document: EP

REN Ceased due to non-payment of the annual fee